New Features In AngioDynamics DuraFlow™ 2 Chronic Hemodialysis Catheter

“The DuraFlow 2 chronic hemodialysis catheter is designed to improve patient outcomes by providing higher blood flow over a longer timeframe with lower recirculation rates”

In short

Vascular access specialist AngioDynamics, has announced the U.S. launch of the next generation DuraFlow™ 2 chronic hemodialysis catheter and the upcoming launch of the DuraFlow™ 2 VascPak® (VP) kit.

Background

AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products.

Along with the DuraMax® chronic hemodialysis catheter, AngioDynamics offers the only 48 cm chronic dialysis catheters on the market, allowing for femoral catheter placements in patients of varying sizes. The DuraFlow 2 catheter continues to provide optimal ease of insertion and sustained high flow rates. A new tough, rigid thermoplastic polyurethane luer increases durability, allowing for more secure fastening to dialysis machines.

The new streamlined VascPak® (VP) kit, set for launch later in 2012,  is designed to meet the needs of many outpatient vascular access centers. Additionally, tray sizes for both the VP and basic kits have been reduced by approximately 30 percent, providing an ideal fit with popular automated medical supply stations and easier handling and storage.

Company comments 

“The DuraFlow 2 chronic hemodialysis catheter is designed to improve patient outcomes by providing higher blood flow over a longer timeframe with lower recirculation rates,” said Alan Panzer, Senior Vice President and General Manager for AngioDynamics. “This latest product evolution features a redesigned kit that is not only more convenient for institutions looking to better control inventories, but also expands the product’s appeal to vascular access centers where 45% of all chronic dialysis catheter placements occur.”

The company makes no mention of its European launch plans in its release.

Source: Angiodynamics